EP2377536
Methods of Using Sustained Release Aminopyridine Compositions
Zusammenfassung
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Anmelder
ACORDA THERAPEUTICS INC [US]
Erfinder
BLIGHT ANDREW R [US]COHEN RON [US]
Externe Quellen
Klassifikation
IPC-Klassen
A61K 31/44
CPC-Klassen
A61K 31/435A61K 31/44A61K 31/4409A61K 9/20A61P 17/02A61P 19/08A61P 21/00A61P 25/00A61P 25/28A61P 43/00
AI: Life Sciences
warum
Acorda fampridine for MS — A61K31/44. Pure pharma.